



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Sugammadex Mylan

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
T/0013	Transfer of Marketing Authorisation	23/10/2024	14/11/2024	SmPC, Labelling and PL	
IB/0012	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	03/07/2024	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



II/0010/G	This was an application for a group of variations. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation	18/04/2024	n/a		
IB/0011	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	18/01/2024	14/11/2024	SmPC and PL	
IAIN/0009/G	This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	14/12/2023	14/11/2024	Annex II and PL	

	B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.II.f.1.e - Stability of FP - Change to an approved stability protocol				
IB/0008	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	31/08/2023	n/a		
N/0007	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	08/06/2023	15/09/2023	PL	
IAIN/0006	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	21/04/2023	n/a		
IB/0004/G	This was an application for a group of variations. B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where	05/04/2023	n/a		

	batch control/testing takes place B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
IB/0005/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	15/03/2023	n/a		

	B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold				
IB/0002/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	05/10/2022	n/a		
IAIN/0003	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	29/09/2022	15/09/2023	Annex II and PL	
IB/0001	To update sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and sections 3 of the PL, in order to change posology recommendations and update safety, efficacy and pharmacokinetic information in children and adolescents (2 - 17 years). Furthermore the MAH has taken this opportunity to amend some local representatives. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following	11/05/2022	02/06/2022	SmPC, Labelling and PL	To update sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and sections 3 of the PL, in order to change posology recommendations and update safety, efficacy and pharmacokinetic information in children and adolescents (2 - 17 years). Furthermore the MAH has taken this opportunity to amend some local representatives.

	assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
--	---	--	--	--	--